MAIA Biotechnology Inc. Stock Price, News & Analysis

MAIA (NYSE American: MAIA) announced on October 7, 2025 a new digital asset treasury strategy permitting corporate officers to buy and sell Bitcoin (BTC), Ethereum (ETH) and USD Coin (USDC).

The Board authorized holdings of up to 90% of the company’s liquid assets in cryptocurrencies and will review transactions, cybersecurity, accounting policies, risks, and material developments. Management said it will keep adequate working capital for operations and seek Board approval to form a Digital Assets Advisory Board to support execution.

MAIA Biotechnology (NYSE American: MAIA) has secured a $2.25 million private placement through the sale of 1,733,766 shares of common stock at $1.30 per share to accredited investors and a Company director.

The offering includes warrants to purchase one share of common stock at $1.57 per share, exercisable after six months with a three-year term. The private placement is expected to close around October 1, 2025. The proceeds will fund Step 1 of Part C of the Phase II THIO-101 trial and working capital needs.

MAIA Biotechnology (NYSE American: MAIA) has secured a $2.3 million NIH grant to expand its THIO-101 Phase 2 clinical trial of ateganosine for advanced non-small cell lung cancer (NSCLC) treatment. The grant will support U.S. patient enrollment over 2025-2027 for third-line treatment of patients resistant to chemo and immunotherapy.

The trial has shown promising results, with median overall survival of 17.8 months in 22 third-line treatment patients, significantly higher than the 5-6 months typical with standard chemotherapy. The trial's expansion phase began in July 2025 in Taiwan, following FDA IND clearance in 2023.

MAIA Biotechnology (NYSE American: MAIA) reported positive Phase 2 clinical trial results for ateganosine (THIO) in combination with cemiplimab for advanced non-small cell lung cancer (NSCLC) patients. The trial showed remarkable efficacy with 5.6 months median progression-free survival in third-line treatment (180 mg dose), more than double the standard of care of 2.5 months.

The study demonstrated an estimated median overall survival of 17.8 months, with confidence intervals showing a lower bound of 12.5 months (95% CI) and 10.8 months (99% CI). Two patients completed 33 treatment cycles, indicating ateganosine's potential for extended dosing. The company has initiated a Phase 2 expansion trial in July 2025 to further validate these promising results.

MAIA Biotechnology (NYSE American: MAIA) announced that its abstract on ateganosine (THIO) treatment for non-small cell lung cancer (NSCLC) has been selected for poster presentation at the 2025 IASLC World Conference on Lung Cancer in Barcelona.

The presentation will highlight promising data from the THIO-101 trial, showing a median overall survival of 17.8 months with a 95% confidence interval lower bound of 12.5 months. Notably, the FDA has recently granted Fast Track designation for ateganosine in NSCLC treatment, potentially expediting its regulatory process towards Accelerated Approval and Priority Review.

MAIA Biotechnology (NYSE American: MAIA) announced the publication of interim clinical data from its Phase 2 THIO-101 trial in the peer-reviewed journal Cells. The manuscript, focused on "Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy," was authored by researchers from Turkey and the U.S., including MAIA's scientific team.

The publication highlights MAIA's novel combination strategy using ateganosine sequenced with a checkpoint inhibitor, which has shown promising results in addressing the challenge of patient resistance to conventional immunotherapies. This development represents a potential breakthrough for patients with high unmet medical needs in non-small cell lung cancer treatment.

MAIA Biotechnology (NYSE American: MAIA) has been granted a European patent for its portfolio of ateganosine-based analogues targeting cancer therapy. The patent covers mercaptopurine ribonucleoside analogues that function as cancer-fighting immunosuppressive agents, disrupting telomere structure and reducing immune system activity to combat cancer cell growth.

The technology, invented by MAIA's CSO Dr. Sergei Gryaznov and Scientific Advisory Board member Dr. Jerry Shay, represents a significant advancement in telomere-targeting compounds with potentially improved cancer cell specificity. The company's global IP portfolio now includes 10 issued patents worldwide, with European validation in 19 countries, and 24 pending patent applications.

MAIA Biotechnology (NYSE American: MAIA) has received FDA Fast Track designation for ateganosine, its first-in-class small molecule treatment for non-small cell lung cancer (NSCLC). The drug, currently in a pivotal Phase 2 THIO-101 clinical trial, has shown promising results with a median overall survival of 17.8 months, significantly outperforming standard treatments that typically achieve 5-6 months survival.

Ateganosine targets telomere structure in cancer cells and works through telomerase-mediated action to reverse resistance to immune checkpoint inhibitors. The company is targeting a $34.1 billion NSCLC market that is projected to reach $68.8 billion by 2033. If successful, MAIA could receive accelerated FDA approval as early as next year.

MAIA Biotechnology (NYSE American: MAIA) announced the publication of preclinical data for its second-generation ateganosine prodrugs platform in Nucleic Acids Research journal. The study focuses on novel telomere-targeting dual-pharmacophore dinucleotide prodrugs for cancer treatment.

The company has developed over 80 ateganosine-like compounds and nominated two key candidates: MAIA-2021-20 (lead) and MAIA-2022-12 (backup). The research demonstrated that these compounds, when combined with immune checkpoint inhibitors, showed superior anticancer efficacy and stronger host immune-memory responses compared to monotherapies. MAIA plans to advance at least one candidate to human clinical trials following completion of required studies.